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The  activation  of  Hageman  factor  is  required  for  the  initiation  of  three 
biologically  active  protein  sequences  in  human  plasma.  The  coagulation  se- 
quence  proceeds  by  the  action  of  activated  Hageman  factor  upon  precursor 
plasma  thromboplastin  antecedent  (pre-PTA)  ~  (1)  and  the  kinin-generating 
pathway by the action of activated Hageman factor or fragments derived from 
activated  Hageman  factor  upon  prekallikrein  (2,  3).  A  third  substrate  of 
activated  Hageman  factor  or  Hageman  factor  fragments,  designated  the 
plasminogen  proactivator,  has  been  separated  from  pre-PTA  and  from  pre- 
kallikrein  and  isolated  free  of  detectable  contanainants.  After  activation  by 
interaction  with  activated Hageman factor or the Hageman factor fragments, 
the active enzyme converts plasminogen to plasmin. 
Materials and Methods 
Bradykinin  triacetate  (Sandoz Pharmaceuticals Ltd., Basel, Switzerland, or New England 
Nuclear  Corp., Boston, Mass.) was used as the standard  for native  bradykinin. Antisera to 
IgG, IgA, IgM, transferrin,  albumin, whole human serum, and  ~2-glycoproteiu I  (Behring 
Diagnostics, Inc., Woodbury, N.Y.);  hexadimethrine  bromide (polybrene) and  diisopropyl- 
phosphofluoridate (DFP)  (Aldrich Chemical Co., Inc., Milwaukee, Wis.); e-aminocaproic acid 
(EACA) (Sigma Chemical Co., St. Louis, Mo.) ; enzodiffusion  fibrin plates  (Hyland Division, 
Travenol Laboratories, Inc., Costa Mesa, Calif.) ; tosyl-L-lysine  chloromethyl ketone (TLCK) 
(Cyclo Chemical Division of Travenol Laboratory, Los Angeles, Calif.); and ampholine carrier 
ampholytes  (LKB,  Rockville,  Md.)  were obtained  as  indicated.  Plasma  thromboplastin 
antecedent  (PTA)-deficient plasma and plasma thromboplastin  component-deficient plasma 
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were  obtained from  Sera-Tec Biologicals, New  Brunswick,  N.J.  Purified  plasminogen was 
a  gift  of  Dr.  E.  C.  DeRenzo  (Lederle  Laboratories,  American  Cyanamid  Co.,  Pearl 
River, N.Y.). 
Serum was processed for the isolation of activated Hageman factor or the Hageman factor 
fragments, while plasma (4) was utilized as a source of the proenzyme substrates prekallikrein, 
pre-PTA,  and  the  plasminogen  proactivator.  Quaternary  aminoethyl  (QAE)  Sephadex 
(Pharmacia Fine  Chemicals,  Inc.,  Uppsala,  Sweden)  and  sulfoethyl  (SE)  Sephadex  chro- 
matography were  performed  utilizing  equilibrating  buffers  containing 0.0035  ~  PO4  (0.8 
m~ho), pH 8.0 and pH 6.0, respectively (4, 5). Sephadex G-100 or G-150 gel filtration (2, 4), 
disc gel electrophoresis (3), and isoelectric focusing in polyacrylamide gels (4, 5) were performed 
as previously described. 
Preparation of an Anti-IgG Immunoadsorbent. -Human IgG was isolated from plasma so as 
to be free of detectable prekallikrein, precursor PTA, and the plasminogen proactivator. The 
effluent obtained from QAE Sephadex chromatography was chromatographed on SE Sephadex, 
and the 0.08-0.10 M NaC1 eluate was then concentrated and chromatographed on Sephadex 
G-150.  The ascending limb of the IgG peak was concentrated to 1 mg/ml, emulsified in com- 
plete Freund's adjuvant, and injected into the four footpads of rabbits at a total dose of 1 mg 
of IgG. 2 wk later, the animals were injected subcutaneously with 1 mg of IgG in incomplete 
Freund's adjuvant and after another 2 wk were bled from the central artery of the ear. The 
antiserum diluted 1/64 gave a  visible precipitin band when diffused  in  Ouchterlony plates 
against 0.5 mg/ml of IgG immunogen, and the undiluted antiserum gave only a  single pre- 
cipitin arc upon immunoelectrophoresis against whole human serum. 
40 ml of the rabbit antiserum were dialyzed against 0.0035 ~ PO4 buffer, pH 8.0, and applied 
to a QAE Sephadex column equilibrated with the same buffer. An initial effluent was collected 
by applying 400 ml of starting buffer and the column then batch eluted with 0.0035  ~  PO4 
buffer, pH 8.0, containing 0.035 ~  NaC1.  These two fractions were pooled, and after concen- 
tration to the starting volume, exhibited the same anti-IgG titer as the whole rabbit serum. 
The anti-lgG was coupled to cyanogen bromide-activated Sephadex G-150 (6) ; coupling was 
performed between pH 7.5 and 8.0 by addition of 1 M HC1  (7).  20 ml of immunoadsorbent 
Were poured into columns and washed with 2 liters of 0.0035 M PO4 buffer, pH 8.0, containing 
0.15 M NaC1.  2 ml of the samples to be adsorbed were applied to the column, the immuno- 
adsorbent was then washed with the equilibrating buffer, and the first 30 ml of effluent con- 
centrated to 2.0 ml. 
]~reparation and  Assay  of Components of the Fibrinolytic  System.  -Activated  Hageman 
factor  was  prepared  by  sequential fractionation  of  plasma  on  QAE  Sephadex,  Sephadex 
G-f00, and carboxymethyl (CM)-cellulose, followed by elutlon from disc gels after electro- 
phoresis at pH 9.3 as previously described (8). Activation of Hageman factor, defined by its 
ability to correct the coagulation defect of Hageman factor-deficient plasma in the absence of 
kaolin occurred during the CM-cellulose chromatography. The prealbumin Hageman factor 
fragments were prepared  after partial isolation of unactivated Hageman factor as follows: 
Plasma dialyzed against 0.0035  ~  PO4 buffer in 0.06 M NaCI at pH 8.0 was applied to QAE 
Sephadex equilibrated with 0.0035  M PO4 buffer, pH 8.0.  The column was batch eluted with 
the dialysis buffer and  the mixture  containing unactivated Hageman factor, prekallikrein, 
pre-PTA,  the plasminogen proactivator, and plasminogen was concentrated to the starting 
volume, activated by stirring in a glass vessel for 24 hr at 4°C, dialyzed against 0.0035 ~  PO4 
buffer, pH  8.0,  and rechromatographed on QAE Sephadex. The Hageman factor fragments 
eluting between 0.23 and 0.28 M NaCI were purified free of other contaminating proteins by 
Sephadex G-100 gel filtration, SE Sephadex chromatography, and elution from disc gels as 
previously described (2). The peak activity of each disc gel eluate was pooled, concentrated, 
and upon reexamination by disc gel electrophoresis revealed a single prealbumin band. Quanti- 
tation on a weight basis was approximated by Folin analysis utilizing albumin as a standard. 1380  FIBRINOLYTIC  PATHWAY  OE  HUMAN  PLASMA 
Plasminogen was prepared by affinity chromatography of 100 ml of plasma utilizing lysine- 
Sepharose columns and e-aminocaproic acid elution as described by Deutsch and Mertz  (9). 
After dialysis against 0.0035  ~  PO4 buffer in 0.15  M NaCI at pH  8,0,  the preparation was 
fractionated by  Sephadex  G-100 gel  filtration employing the dialysis buffer. The  fractions 
containing plasminogen,  as  assessed  by  streptokinase activation and  application to  fibrin 
plates, were pooled and concentrated to 10 ml; examination of the plasminogen preparation 
by disc gel electrophoresis revealed a single broad band identified as plasminogen by functional 
analysis of an unstained sliced replicate disc gel  (Fig.  1).  The isoelectric point of the plas- 
minogen based upon functional analysis of the eluates  of  the acrylamide gel slices ranged 
from pH 6.3 to 8.6 in agreement with the charge heterogeneity previously reported for purified 
plasminogen  (10).  Staining of replicate gels demonstrated multiple bands extending through 
this pH range. 
Plasmin was assayed utilizing Hyland fibrin plates. A standard curve relating ring diameter 
to  plasmin  concentration was  obtained  by  activating  a  reference  preparation  of  purified 
plasminogen, 250 #g/ml (11), with 140 units of streptokinase for 30 min at 37°C; a linear plot 
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F~6.  1.  Alkaline disc gel  electrophoresis of  purified plasminogen, Beneath is shown the 
plasmin generated by streptokinase activation of the eluate of each slice of a  repilcate, un- 
stained disc gel. 
relating log  concentration plasmin  to  ring  diameter  was  obtained  between  3  and  250  #g 
plasmin/ml (Fig. 2). The plasminogen isolated as described above was assayed by incubation 
with 550  units of  streptokinase/mg of  plasminogen and had an  activity on a  weight basis 
similar to the standard preparation. During isolation procedures, plasminogen was routinely 
identified by interaction of 100/zl of the various fractions with 5/zl of streptokinase containing 
165 units and determining the plasmin generated. 
Other substrates of  activated Hageman  factor, prekallikrein  (4),  and pre-PTA  (4)  were 
assayed functionally as previously described in terms of kinin generation and correction of the 
partial  thromboplastin  time  of  PTA-deficient  plasma,  respectively.  The  inhibitor  of  the 
activated first component of complement (CIlNH), prepared by a modification of the method 
described in  (12),  gave no precipitin band upon immunoelectrophorefic analysis with anti- 
serum to whole human serum, to  at-antitrypsin, or to a2-macroglobuliu but did precipitate 
with antiserum to CIlNH. 
RESULTS 
Purification  of the Plasminogen  Proactivator 
In  order  to  seek the  precursor  form of  a  protein  involved in  plasminogen 
activation,  fractions  of  human  plasma  were  interacted  with  the  Hageman ALLEN  P.  KAPLAN AND  K.  FRANK  AIISTEN  1381 
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factor fragments and then with plasminogen. The effluent obtained from QAE 
Sephadex  chromatography of  100  ml  of plasma,  upon  interaction  with  the 
Hageman factor fragments, led  to the conversion of plasminogen  to plasmin 
(Fig. 3). The effluent had no plasminogen-converting activity in the absence of 
the Hageman factor fragments. Neither the effluent nor the eluate contained 
kallikrein,  PTA,  activated  Hageman  factor,  Hageman  factor  fragments,  or 
plasmin,  indicating  that  these  enzymes had  remained in the precursor state 
during  chromatography.  After  application  of  a  sodium  chloride  gradient, 
unactivated Hageman factor was  eluted between 0.04  and 0.06 M NaC1  and 
plasminogen between 0.06 and 0.09 M NaC1; none of the eluate fractions con- 
tained material capable of converting plasminogen to plasmin with or without 
the addition of Hageman factor fragments. 
The effluent from  the  QAE  Sephadex chromatogram  was  pooled,  concen- 
trated to 10 ml, and again assayed for its capacity to convert plasminogen to 
plasmin.  The failure of streptokinase alone to induce fibrinolysis in the plate 
demonstrates that the fibrin plate lacked plasminogen. Incubation of Hageman 
factor fragments with plasminogen alone or incubation of the QAE Sephadex 
effluent with plasminogen gave no  conversion to plasmin.  Incubation of the 
Hageman factor fragments with the effluent for 10 min at 37°C  followed by 
incubation of the mixture with plasminogen, 200#g/ml, for 1 hr at 37°C yielded 
a ring of fibrinolysis equivalent to the generation of 80 #g of plasmin, confirming 1382  ]~'IBRINOLYTIC PATHWAY  OF  tIUMAN  PLASN[A 
the presence of a function designated the plasminogen proactivator in the con- 
centrated  effluent  (Fig.  4). 
The concentrated QAE Sephadex effluent was then chromatographed on SE 
Sephadex to determine the relationship of the plasminogen-activating activity 
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FIG. 3.  QAE Sephadex chromatography of plasma with analysis of the eluate (above) and 
effluent (below). 
Fie. 4. Fibrin plate assay of the concentrate of the QAE Sephadex effluent shown in Fig. 3. 
STREP,  streptokinase; QAE  EFF, QAE  Sephadex effluent; PLG, plasminogen;  HAG  Ff , 
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to the pre-PTA  and prekallikrein also  present in this fraction (Fig. 5). After 
application of a  linear sodium chloride gradient, prekallikrein was eluted be- 
tween 0.12  and 0.14 ~  NaC1,  precursor PTA between 0.16  and 0.19 M NaCI, 
and the plasminogen proactivator in a  region between but overlapping both 
prekallikrein  and  pre-PTA.  The  plasminogen  proactivator  peak  shown  in 
Fig. 5 was divided in half by pooling tube Nos. 90 to 120 and Nos. 121 to 160, 
so as to obtain one pool contaminated predominantly with prekallikrein and the 
other with precursor PTA and to a lesser degree with prekallikrein. Each pool 
was then concentrated to 2 ml and fractionated on Sephadex G-150. The first 
SE Sephadex pool, as shown in Fig. 6 A, revealed prekallikrein along the de- 
scending limb  of the IgG peak  and  the plasminogen proactivator  along the 
descending limb of the prekallikrein peak. The second SE Sephadex pool, shown 
in Fig. 6 B, revealed pre-PTA along the ascending portion of the IgG peak and a 
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FIG. 6. Sephadex G-150 chromatography of pools from tube Nos. 90 to 120  (A) and tube 
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small  prekallikrein peak preceding the position of the plsasminogen proacti- 
vator. When the plasminogen proactivator peak shown in Fig. 6 B was pooled, 
concentrated to  2  ml,  and  rechromatographed on Sephadex G-150,  the plas- 
minogen proactivator obtained after concentration to the starting volume was 
free of prekaliikrein and contained trace quantities of IgG as the sole identifi- 
able contaminant. The entire sample was then applied to the anti-IgG immuno- 
adsorbent,  the effluent concentrated to  2 ml,  and  a  portion focused in poly- 
acrylamide gels  utilizing ampholytes ranging  from pH  7  to  10.  As  shown in 
Fig. 7, the stained gel had a single band; functional assessment of a replicate 
FIC. 7. Isoelectric focusing in polyacrylamide  gels of purified plasminogen proactivator 
utilizing pH 7-10 ampholytes.  Beneath is shown the assay for plasminogen proactivator of the 
eluate of each slice of a replicate,  unstained gel. 
sliced,  unstained  gel  revealed the  plasminogen proactivator peak  at  pH  8.9, 
the position of the stained band. 
Prekallikrein (Fig. 6 A) and pre-PTA (Fig. 6 B) obtained from the Sephadex 
G-150 step were isoelectric at pH 8.75 and pH 9.1, respectively, as determined 
by elution and functional assessment, while plasminogen proactivator was iso- 
electric at pH 8.9. Fractionation of pre-PTA, prekallikrein, and the plasminogen 
proactivator obtained at the Sephadex G-150 step in the presence of substances 
of known molecular weight  revealed estimated molecular weights  of  175,000 
for pre-PTA,  127,000  for prekallikrein,  and  i00,000 for the plasminogen pro- 
aetiwttor (Fig. 8). 
Conversion of Ylasminogen  to Plasmin by the Plasminogen Activator 
The plasminogen proactivator peak at the stage of purification illustrated in 
Fig.  6  B  was  concentrated to  2  ml,  and  100 #1  were incubated  with  2  #1  of ALLEN P.  KAPLAN AND  K.  FRANK AUSTEN  1385 
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FIG. 8. Molecular weight estimation of three substrates of active Hageman factor by gel 
filtration on Sephadex G-150. "£he K~ of the marker proteins IgG, transferrin, and albumin 
are shown on the left. 
Hageman factor fragments, 25 #g/m], for 1 hr at 37°C.  20 #1 of this mixture 
were then incubated with 20 #1 of plasminogen,  200 #g/ml,  for 1 hr at 37°C, 
and  46  ~tg/ml  plasmin  was  generated.  Incubation  of  the  plasminogen  pro- 
activator with  quantities  of the Hageman factor fragments up  to  2.5  #g for 
periods  ranging from  1 to  6  hr  did not  reveal further plasminogen activator 
activity. 
The plasminogen activator formed as described above from 100/~1 of plas- 
minogen proactivator and  2 #l  of Hageman factor fragments was  diluted  as 
shown in Fig. 9 and 20 #1 of each dilution incubated with 20/~l of plasminogen 
for 2 hr at 37°C. A straight line was obtained relating dilution of plasminogen 
activator to plasmin generated. These dilutions of plasminogen activator gave 
the same yield of plasmin when the plasminogen substrate was diluted  1:4 so 
that  the  maximum plasminogen  made  available by streptokinase  activation 
was 50 #g/ml. Incubation of the plasminogen activator with excess plasminogen 
for periods up to 3 hr gave minimal further increases in the quantity of plasmin 
as compared with incubation for 15 rain; incubation for a further 9 hr revealed 
conversion of additional plaslninogen to plasmin. 
Inhibition of the Plasminogen Activator and P/asmin 
Active Site Inhibitors.--DFP, an active site serine inhibitor,  and TLCK, an 
active site histidine  inhibitor,  were  examined  for  their  ability to  inhibit  the 
plasminogen  activator and plasmin.  Plasminogen proactivator obtained  from 
the Sephadex G-150 step (Fig. 6 B) and activated as described above generated 1386  FIBRINOLYTIC  ~ATIIWAY  OF  IIUI~IAN  PLASMA 
50 #g/'ml of plasmin from plasminogen.  The plasminogen activator was incu- 
bated for 90 rain at 37°C with either buffer alone, or sufficient DFP  or TLCK 
to yield a final concentration of 10  4  ~. Each reaction mixture was then dialyzed 
overnight against 0.0035 5~ PO4 buffer, pit 8.0, containing 0.015 g  NaCI. The 
same  preparation  of  plasminogen  proactivator  was  incubated with  the  same 
materials,  dialyzed  overnight,  and  then  activated  with  the Hageman  factor 
fragments. 20 ~1 of each of these six samples were then incubated with 20 #1 of 
plasminogen, 200 #g/ml,  for 1 hr at 37°C,  and the conversion to plasmin was 
assessed  on fibrin plates.  As shown in Fig.  10,  incubation of the plasminogen 
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Fro.  9.  Graph relating dilution of plasminogen activator  to plasmin generated from a  con- 
stant input of plasminogen. 
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FIO.  10.  Inhibition  of the plasminogen  activator  and  plasmin  by  DFP  and  TLCK.  (A) 
Plasminogen  activator  and  plasminogen.  (B)  Plasminogen  activator  made  10  .3  ~  in  DFP 
and  plasminogen,  ((7)  Plasminogen  activator  made  10  -3  ~  in TLCK  and  plasminogen.  (D) 
Plasminogen proactivator  and Hageman factor fragments and plasminogen.  (E)  Plasminogen 
proactivator  made  10  .3  ~  in  DFP  and  Hageman  factor  fragments  and  plasminogen.  (F) 
Plasminogen  proactivator  made  10  .8  ~  in  TLCK  and  Hageman  factor  fragments  and 
plasminogen.  (G)  Plasmin  made  10  -3  ~  in  DFP.  (H)  Plasmin  made  10  -~ ~  in TLCK.  (I) 
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activator  with  DFP  (B)  resulted  in  90%  inhibition,  while  incubation  with 
TLCK resulted in 20 % inhibition  (C). The plasminogen proactivator retained 
over 90%  of its  ability  to  convert  plasminogen  to  plasmin  (D,  E,  F).  The 
plasmin  resulting  from  the  interaction  of  the  plasminogen  activator  and 
plasminogen (A) was made 10  -3 M in DFP or 10-  3 ~  in TLCK, dialyzed, and 
its functional integrity determined.  10-  3 ~  DFP resulted in 18% inhibition of 
plasmin (G), whereas 10-  3 z~ TLCK yielded 96 % inhibition (//). Increasing the 
dose of DFP to 10-  2 ~  yielded 90% plasmin inhibition (/). 
Action of EACA.--EACA,  a  known inhibitor of plasmin  (13)  and  of  plas- 
minogen activation (13,  14),  was examined for its effect upon the plasminogen 
activator.  A  preparation  of  plasminogen  proactivator  obtained  from  the 
Sephadex  G-150  step  (Fig.  6  B)  was  activated  and  generated  90  #g/ml  of 
plasmin  from plasminogen.  This  plasminogen  activator  was  incubated  with 
plasminogen for 1 hr at 37°C in the presence of final concentrations of EACA 
ranging from 0.025  M to 0.2 M. For comparison, the plasminogen activator was 
incubated  with  plasminogen  for  1  hr  at  37°C  and  the  EACA  added  subse- 
quently to achieve the same final concentrations as above. The incubation with 
EACA was carried out for 1 hr before assay. The area between the two plots 
reflects the capacity of EACA to prevent conversion of plasminogen to plasmin 
by the plasminogen activator beyond any effect on the assay through inhibition 
of the plasrnin generated (Fig. 11). 
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FIG. 11. The effect of EACA at concentrations ranging from 0.025 ~  to 0.2 ~ upon plas- 
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E~ect of CIlNH.--1 ml of the concentrated QAE Sephadex effluent (Fig. 3) 
was activated with 50 #l of Hageman factor fragments, 25 #g/ml, to yield kalli- 
krein and plasminogen activator. 500/A of the reaction mixture were incubated 
with either equal volumes of buffer or CIINH 130,000 units/ml. The mixtures 
were dialyzed for 41/~ hr against 0.0035 ~  P04 buffer, pH 8.0,  and  each  was 
applied to a 2 X  10 cm column of QAE Sephadex previously equilibrated with 
the dialysis buffer. 30 ml of effluent were collected, concentrated to 1 ml, and 
assayed for kallikrein and plasminogen activator. As shown in Table I, 5000 
ng  of  bradykinin/ml  were  generated  from  heat-inactivated  plasma  as  a 
source of kininogen while less than 10 ng of bradykinin was generated when the 
initial effluent was previously interacted with CIINH to inhibit kallikrein. In 
contrast, the effluent generated the same quantity of plasmin from plasminogen 
(32-33 #g/ml) irrespective of the prior interaction of the plasminogen activator 
of the initial effluent with the CIINH. CIINH was not present in the effluent 
TABLE  I 
Effect of CIlNH on Kallikrein vs. Plasminogen Activator 
Kallikrein  Plasrninogen activator 
ng bradykinin/ml generated  ~g plasmin/ml generated 
QAE effluent and buffer  5000  33 
QAE effluent and  <  10  32 
C]INH 
as assessed  by hemolytic titrations and thus the C-IINH input could not have 
influenced the assay of kallikrein. 
DISCUSSION 
The activation of Hageman factor in plasma is known to result in the de- 
velopment of fibrinolytic activity which is not attributable to the direct action 
of activated Hageman factor (15-17)  or its fragments (Fig. 4) upon plasmino- 
gen. The conversion of plasminogen proactivator to plasminogen activator by 
activated  Hageman factor has  been  recognized  as  an  essential  step  in  the 
fibrinolytic sequence. The plasminogen proactivator was isolated from normal 
human plasma by sequential chromatography using QAE  Sephadex  (Fig. 3), 
SE Sephadex (Fig. 5), and Sephadex G-150 gel filtration (Fig. 6). The location of 
the  plasminogen  proactivator  during  the  chromatographic  procedures  was 
recognized using purified Hageman factor fragments for activation and purified 
plasminogen  (Fig.  1)  as substrate  for plasminogen activator  (Fig.  7).  These 
procedures  separated  plasminogen  proactivator  from  two  other  proenzyme 
substrates of activated Hageman factor, prekallikrein and pre-PTA (Figs. 5, 6). 
The contaminating IgG was then removed by using an immunoadsorbent and 
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gel  electrophoresis or isoelectric focusing in polyacrylamide gels  which corre- 
sponded to the position of the functional material eluted from unstained gels 
(Fig. 7). 
The isoelectric point of the plasminogen proactivator, pH  8.9  (Fig.  7),  is 
intermediate  between  that  of  the  other  two  substrates  of  active Hageman 
factor, kallikrein, pH 8.75; and pre-PTA,  pH 9.1.  The plasminogen proacti- 
vator  has  an  estimated molecular weight  of  100,000 (Fig.  8)  by  Sephadex 
G-150  gel  filtration,  a  procedure  giving  an  estimated  molecular  weight  of 
127,000 for prekallikrein and 175,000 for pre-PTA.  Although the  proenzymes 
of kallikrein and plasminogen activator are similar in size and isoelectric point, 
a  difference in the functional characteristics of their active sites further dis- 
tinguished these two proteins. Kallikrein is known to be inhibitable by CIINH 
(18, 19) and when present in a mixture with plasminogen activator, kallikrein 
was completely inhibited by a  concentration of CIINH which had no effect 
upon  the  plasminogen  activator  (Table  I).  The  active  site  in  plasminogen 
activator is susceptible to inactivation by DFP  (Fig.  10)  but not by a  com- 
parable concentration of TLCK. The active site in the plecursor molecule, the 
plasminogen proactivator, is protected from DFP inactivation as has been the 
case for many proesterases having a serine in the active site. 
Ogston et al. have described an active enzyme dependent upon prior Hage- 
man  factor  activation,  termed  Hageman factor  cofactor,  which  is  required 
for the fibrinolytic pathway (17). The plasminogen activator is similar to the 
Hageman factor cofactor in its properties during ion exchange chromatography 
and in the inability of C]-INH to inhibit its action upon plasminogen. However, 
the estimated molecular weight of the Hageman factor cofactor (165,000) is 
greater than that of the plasminogen activator isolated directly from serum, 
which is comparable in size to the plasminogen proactivator (100,000). The iso- 
lation of Hageman factor cofactor following a  variety of precipitation pro- 
cedures  could  have  favored  formation  of  a  plasminogen  activator-plasmin 
complex or may have permitted aggregation. 
The interaction of the plasminogen activator with plasminogen for a limited 
time period is characterized by a yield of plasmin proportional to the plasmino- 
gen activator concentration (Fig. 9). When there is plasminogen excess during 
the limited time period, as assessed by streptokinase activation, only a fraction 
of  the  available plasminogen is  activated for  a  given input  of plasminogen 
activator. These reaction characteristics are similar to the kinetics of plasmino- 
gen activation reported by Colman utilizing a  kallikrein source,  presumably 
containing plasminogen activator, to activate plasminogen and casein as the 
plasmin substrate (20). Such kinetics are consistent with binding of plasminogen 
activator with plasminogen to form a complex.  After prolonged interaction of 
plasminogen activator and plasminogen, there is a second phase of plasminogen 
activation. These two steps are reminiscent of the interaction of streptokinase 
with  plasminogen.  Initially,  a  streptokinase-plasminogen  complex  forms 1390  FIBRINOLYTIC  PATHWAY  OF  HUMAN  PLASMA 
stoichiometrically,  converts to  an  active  streptokinase-plasmin  complex  (21- 
23), and this complex or a fragment therefrom (24, 25)  activates plasminogen 
catalytically (22, 24). Takada et al. have described a streptokinase activatable 
proactivator of plasminogen  which is present in human  plasma;  at very low 
doses of streptokinase, this factor may be activated to a plasminogen  activator 
with  little  direct  activation  of  plasminogen  by the  streptokinase  (26).  The 
plasminogen  proactivator described herein  is not activatable by streptokinase. 
Further the plasminogen proactivator is not converted to plasminogen  activator 
by human plasmin derived by streptokinase activation or by plasmin develop- 
ing spontaneously during the affinity chromatographic isolation of plasminogen. 
Finally,  the plasminogen  activator, kallikrein,  and PTA do not  activate the 
plasminogen  proactivator.  Intact  activated Hageman  factor or its fragments 
represent  the  only molecules  recognized  thus  far  capable of converting  the 
plasminogen  proactivator  to  plasminogen  activator. 
A summary of the pathways resulting  from the activation of three Hageman 
factor substrates is shown in Fig. 12. Although the Hageman factor prealbumin 
fragments have been routinely used to activate the plasminogen  proactivator in 
the present studies,  intact activated Hageman factor or any of the previously 
described  intermediate  sized  fragments  of  activated  Hageman  factor  (3) 
readily  activate  the  plasminogen  proactivator.  Intact  activated  Hageman 
factor is converted to the fragments by digestion with plasmin (3) thus divert- 
ing the reaction sequence from coagulation  to kinin generation.  The insertion 
of EACA at the time of Hageman factor activation in the fluid phase has been 
found to protect the active Hageman factor from fragmentation and to diminish 
the rate of conversion  of prekallikrein  to kallikrein  (8). The capacity of EACA 
to bind to plasminogen  (9,  27, 28)  and inhibit  the action of the plasminogen 
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activator upon plasminogen  (Fig.  11)  would be consistent with such an  effect 
and with the over-all reaction scheme as postulated. 
SUMMARY 
The conversion of the plasminogen proactivator to plasminogen activator by 
activated Hageman factor or its fragments has been recognized as an essential 
step in the conversion of plasminogen to plasmin. The plasminogen proactivator 
has been completely separated from prekallikrein and pre-PTA, two other pro- 
enzyme substrates of activated Hageman factor or its fragments. Plasminogen 
proactivator, free of any contaminating proteins as assessed by disc gel electro- 
phoresis or isoelectric focusing, revealed a single band with an isoelectric point 
of 8.9  corresponding in  position  to  the Hageman factor activatable material 
eluted  from  replicate  unstained  gels.  After  conversion  of  plasminogen  pro- 
activator by Hageman factor fragments to the plasminogen activator, the active 
site of the plasminogen activator is not inhibited by CIINH and is thus readily 
distinguished  from  that  of kallikrein  or PTA.  The  plasminogen  activator is 
susceptible to inactivation by DFP while the plasminogen proactivator is not, 
as has been the case for esterases having a  serine in the active site.  Its inter- 
action with plasminogen is inhibited by e-aminocaproic acid. 
The authors wish to acknowledge the excellent technical assistance of Ms. Irma Finks and 
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